GlaxoSmithKline sounds taps for a once-mighty R&D program
You could call it a follow-up case of an anti-inflammatory flop for GlaxoSmithKline.
A year after GSK shrugged off the failure of losmapimod in protecting high-risk heart failure patients, the pharma giant says it will now shutter its R&D effort for this drug on COPD. That news was buried in its Q3 release Wednesday morning.
Two years ago GSK had mapped out ambitious plans to put losmapimod through a huge development program, looking for data to prove that the therapy could prevent repeat heart attacks. But that fell through last fall when the pharma giant was forced to concede that the drug had proven to be a bust in the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.